2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N13247
    Ajuga Turkestanica Extract
    Ajuga Turkestanica Extract is a muscle grass extract. Ajuga Turkestanica Extract can increase Notch and Wnt signaling in triceps brachii, and has potential skeletal muscle protection..
    Ajuga Turkestanica Extract
  • HY-N13248
    Mulberry Leaf Extract 98%
    Mulberry Leaf Extract is a mulberry leaf extract, and its components include: 1-Deoxynojirimycin. Mulberry Leaf Extract can effectively alleviate the adverse effects of high-fat diet on blood lipids and renal function, regulate lipid metabolism abnormalities, and significantly inhibit the accumulation of glycosylated substances in glomeruli. Mulberry Leaf Extract can regulate the key signaling pathways of diabetic nephropathy, but does not directly affect blood glucose levels..
    Mulberry Leaf Extract
  • HY-N1480S
    (-)-Fucose-13C 83379-38-8 99.86%
    (-)-Fucose-13C is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti
    (-)-Fucose-13C
  • HY-N1499R
    Nystose (Standard) 13133-07-8 99.73%
    Nystose (Standard) is the analytical standard of Nystose. This product is intended for research and analytical applications. Nystose is a tetrasaccharide with two fructose molecules linked via beta (1→2) bonds to the fructosyl moiety of sucrose. Nystose exhibits prebiotic, immunomodulatory, and metabolism regulating activities. Nystose promotes the bone mineralization by activating the Wnt/β-catenin signaling pathway.
    Nystose (Standard)
  • HY-N19066
    Cissus quadrangularis extract 98%
    Cissus quadrangularis extract contains a variety of bioactive compounds, such as flavonoids, phenolic acids, carotenoids, triterpenoids, vitamins, 3-ketosteroids, minerals, and sterols. Cissus quadrangularis extract can promote fracture healing, reduce bone loss, and increase bone density.
    Cissus quadrangularis extract
  • HY-N2302R
    Fucoxanthin (Standard) 3351-86-8
    Fucoxanthin (Standard) is the analytical standard of Fucoxanthin. This product is intended for research and analytical applications. Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.
    Fucoxanthin (Standard)
  • HY-N2341S
    Palmitelaidic acid-d13 2692623-91-7 99.0%
    Palmitelaidic acid-d13 is the deuterium labeled Palmitelaidic Acid. Palmitelaidic Acid (9-trans-Hexadecenoic acid) is the trans isomer of palmitoleic acid. Palmitoleic acid is one of the most abundant fatty acids in serum and tissue.
    Palmitelaidic acid-d13
  • HY-N2362S
    DL-Alanine-13C-1 102029-81-2 98.0%
    DL-Alanine-13C-1 is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver.
    DL-Alanine-13C-1
  • HY-N6740S
    β-Zearalanol-d4 1778735-09-3 99.24%
    β-Zearalanol-d4 is a deuterium labeled Beta-Zearalanol (HY-N6740）. Beta-Zearalenol is an mycotoxin produced by Fusarium spp, which causes apoptosis and oxidative stress in mammalian reproductive cells. Beta-Zearalenol is the derivative of zearalenone (ZEA) which can conjugate with glucuronic acid.
    β-Zearalanol-d4
  • HY-N7088R
    Raffinose (Standard) 512-69-6 99.81%
    Raffinose (Standard) is the analytical standard of Raffinose. This product is intended for research and analytical applications. Raffinose (Melitose) regulates intestinal flora, inhibits TLR4-MyD88-NF-κB signaling pathway, and activates Nrf2 signaling pathway. Raffinose exhibits anti-inflammatory, antioxidant, and immunomodulatory activities. Raffinose is orally active.
    Raffinose (Standard)
  • HY-N7697F
    Chitobiose 577-76-4 98%
    Chitobiose is an orally active chitosan oligosaccharide (degree of polymerization 2). Chitobiose shows hepatoprotective activity and counteracts CCl4-induced elevation of plasma aspartate transaminase and alanine transaminase activities in rats. Chitobiose can be used for the research of carbon tetrachloride-induced acute hepatotoxicity.
    Chitobiose
  • HY-N9944R
    3-Oxo-4,6-choladien-24-oic acid (Standard) 88179-71-9 99.94%
    3-Oxo-4,6-choladien-24-oic acid (Standard) is the analytical standard of 3-Oxo-4,6-choladien-24-oic acid. This product is intended for research and analytical applications. 3-Oxo-4,6-choladien-24-oic acid is an endogenous metabolite. 3-Oxo-4,6-choladien-24-oic acid exsists in the urine of patients with hepatobiliary disease[1].
    3-Oxo-4,6-choladien-24-oic acid (Standard)
  • HY-P0149A
    Katacalcin TFA 99.55%
    Katacalcin TFA (PDN 21 TFA) is a potent plasma calcium-lowering peptide.
    Katacalcin TFA
  • HY-P10302
    GLP-1R/GIPR agonist-1 98%
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
    GLP-1R/GIPR agonist-1
  • HY-P10341
    ZP3022 1345835-12-2 98.00%
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research.
    ZP3022
  • HY-P10397
    YHIEPV 2243939-21-9 99.85%
    YHIEPV (rALP-2, Rubisco anxiolytic-like peptide 2) is a potent and orally active peptide. YHIEPV shows anxiolytic effects. YHIEPV increases leptin sensitivity to exert its anti-obesity effects.
    YHIEPV
  • HY-P10399
    KGYY15 1690215-31-6 99.19%
    KGYY15 (Mouse KGYY15) is a CD40 targeting peptide, which weakly inhibits the CD40-CD40L interaction with IC50 of more than 1mM. KGYY15 activates 33% NF-κB pathway at 100 μM.
    KGYY15
  • HY-P10413
    SHBG(141–161) 98.78%
    SHBG 141-161 is a GPRC6A receptor agonist. SHBG 141-161 mimics the action of GPRC6A endogenous agonist uncarboxylated osteocalcin by binding to GPRC6A and promoting downstream signaling to increase testosterone and insulin secretion. SHBG 141-161 also reduces the affinity of GPRC6A to GDP protein by binding to the outer cell domain of GPRC6A thus affecting the dynamics of signal transduction. SHBG 141-161 can be used to study GPRC6A in energy metabolism and endocrine regulation.
    SHBG(141–161)
  • HY-P1064A
    Apelin-36(human) TFA 99.42%
    Apelin-36(human) TFA is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) TFA shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC550=8.61). Apelin-36(human) TFA has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ.
    Apelin-36(human) TFA
  • HY-P10809
    VAMP 3103992-61-3 98.13%
    VAMP, a tetrapeptide, is a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 1.00 μM and a Kd of 6.89 μM. VAMP effectively targets the DPP-IV-GLP-1 axis and can be used for the study of type 2 diabetes.
    VAMP
Cat. No. Product Name / Synonyms Application Reactivity